Please be advised that the ANZCTR will be unattended on Monday the 28th of January due to the Australia Day public holiday.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613001041741
Ethics application status
Approved
Date submitted
16/09/2013
Date registered
18/09/2013
Date last updated
14/01/2016
Type of registration
Prospectively registered

Titles & IDs
Public title
Short term effects of palm-tocotrienols and palm-carotenes on vascular function and cardiovascular disease risk in individuals at increased risk of impaired vascular function.
Scientific title
Will short-term supplementation with palm-tocotrienols and palm-carotenes improve endothelial function as measured by brachial artery flow mediated dilation in participants with increased risk of impaired vascular function compared to control?
Secondary ID [1] 283207 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiovascular disease risk 290067 0
Type 2 diabetes 290118 0
Impaired fasting glucose 292670 0
Abdominal obesity 293541 0
Condition category
Condition code
Cardiovascular 290449 290449 0 0
Diseases of the vasculature and circulation including the lymphatic system
Metabolic and Endocrine 290500 290500 0 0
Diabetes
Alternative and Complementary Medicine 290501 290501 0 0
Other alternative and complementary medicine

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Participants will consume one of the following two interventions for a duration of 8 weeks:

* 500mg/d palm tocotrienols in the form of two palm olein capsules/d to be consumed orally with the main meal.

OR

* 21mg/d palm carotenes in the form of three palm olein capsules to be consumed orally with the main meal.

Compliance will be monitored by counting of returned capsules and by measuring plasma tocotrienol and carotenoid concentrations using HPLC.
Intervention code [1] 287932 0
Prevention
Intervention code [2] 287975 0
Treatment: Other
Comparator / control treatment
800mg/d palm olein in the form of two capsules to be consumed orally with the main meal.
Control group
Active

Outcomes
Primary outcome [1] 290475 0
Endothelial function measured by brachial artery flow mediated dilation
Timepoint [1] 290475 0
Baseline, 4 weeks, 8 weeks
Secondary outcome [1] 304576 0
Blood pressure using automated oscillometry
Timepoint [1] 304576 0
Baseline, 4 weeks, 8 weeks
Secondary outcome [2] 304714 0
Glucose metabolism
* Insulin and glucose using plama assays
* Insulin resistance by calculating HOMA2-IR
* HbA1c using HPLC
Timepoint [2] 304714 0
Baseline, 4 weeks, 8 weeks
Secondary outcome [3] 304715 0
Lipid profiles (total cholesterol, HDL-C, LDL-C, triglycerides) using plasma assays
Timepoint [3] 304715 0
Baseline, 4 weeks, 8 weeks
Secondary outcome [4] 304716 0
Plasma inflammatory markers (hs-CRP, IL-6, TNFalpha, adiponectin) using multiplex kits
Timepoint [4] 304716 0
Baseline, 4 weeks, 8 weeks
Secondary outcome [5] 304717 0
Plasma adhesion molecules (ICAM-1, VCAM-1, E-selectin) using multiplex assays
Timepoint [5] 304717 0
Baseline, 4 weeks, 8 weeks
Secondary outcome [6] 304718 0
Endothelium derived fibrinolytic factors:
* tPA using plasma assays
* PAI-1 using mulitplex assays
Timepoint [6] 304718 0
Baseline, 4 weeks, 8 weeks
Secondary outcome [7] 304719 0
Arterial stiffness using pulse wave velocity and augmentation index
Timepoint [7] 304719 0
Baseline, 4 weeks, 8 weeks

Eligibility
Key inclusion criteria
*Male or female
*Type 2 diabetes (previously diagnosed and taking anti-diabetic medication or HbA1c of 7.0-10.0%) or impaired fasting glucose (fasting plasma glucose of 5.6 mmol/L and greater) or abdominal obesity identified by elevated waist circumference: equal of greater than 102 cm (men); equal or greater than 88 cm (women).
*18-70 years
* BMI: 20-45 kg/m2
* No abnormality of clinical significance on medical history
* No history of coronary artery disease or cardiac (heart) abnormalities
Minimum age
18 Years
Maximum age
70 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Type 1 diabetes
* Smoking
* Known proteinuria or current malignancy
* Known kidney, respiratory, gastrointestinal, cardiovascular or peripheral vascular disease
* Known abnormal liver function tests
* Known endocrinopathy unless participants are stable on treatment (have been using thyroxine for at least 3 months prior to study commencement (no changes in type and dose) and have no intention to change during study).
* Pregnancy or lactating
* Participated in regular vigorous physical exercise greater than 1 hour per week or greater than 2x, 30 minute sessions / week during the 3 months prior to the study
* Have taken tocotrienol or carotene supplements during the 3 months prior to study
* Taking supplements known to affect outcome measures (i.e. fish oil, vitamin C) unless supplements are ceased before trial commencement (3 months for fish oil, 2 weeks for vitamin C) or participants are stable on the supplements for at least 3 months prior to study commencement (no changes in type and dose) and have no intention to change during study.
* Use of nitrate medication, non-steroidal anti-inflammatory medication (excluding aspirin)
* Taking oral contraceptives or hormone replacement therapy during the 3 months prior to study
* History of heavy alcohol consumption (> 5 STD drinks/day)
* Volunteer unable to limit alcohol consumption for study duration
* Currently on a weight reducing diet or have an eating disorder
* Unwilling to be randomized to either experimental group
* Extended absences due to travel or other commitments
* Unable to comprehend or cope with study requirements

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants who are eligible will be enrolled in the project and allocated to an intervention code based on a computer generated randomization scheme. Individuals who enrol and allocate particpants to interventions will be blind to intervention codes. The coded supplements will be concealed by using identical opaque drug containers.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Eligible participants will be assigned to the interventions using stratified random assignment based on diabetic/impaired fasting glucose state, age, gender, weight and medication. The randomization scheme will be computer generated.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint(s)
Efficacy
Statistical methods / analysis
The power for this study is based on detecting differences for the a priori hypothesis based on comparisons between the palm-carotene vs placebo and palm-tocotrienol vs placebo for the primary outcome measure of FMD. The study will commence with 30 subjects in each group. Based our previous trials, with an anticipate dropout rate of 10% and at least 27 subjects per group completing the study we will have enough power (80%, alpha = 0.05) to detect a minimum absolute difference of 1.8% between the group comparisons for FMD. An improvement in FMD of 2% (absolute) magnitude has previously been associated with a clinically relevant reduction in CVD risk.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 287950 0
Commercial sector/Industry
Name [1] 287950 0
Pemandu (Prime Ministers Development of the Goverment of Malaysia) / MPOB (Malaysian Palm oil Board)
Address [1] 287950 0
Food Technology & Nutrition Unit,
Product Development & Advisory Services Division,
Malaysian Palm Oil Board
P.O. Box 10620
50720 Kuala Lumpur
Country [1] 287950 0
Malaysia
Primary sponsor type
Government body
Name
CSIRO Animal, Food and Health Sciences
Address
PO Box 10041
Adelaide BC SA 5000
Country
Australia
Secondary sponsor category [1] 286669 0
None
Name [1] 286669 0
Address [1] 286669 0
Country [1] 286669 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 289877 0
CSIRO Human Ethics Committee
Ethics committee address [1] 289877 0
PO Box 10041
Adelaide BC
SA, 5000
Ethics committee country [1] 289877 0
Australia
Date submitted for ethics approval [1] 289877 0
Approval date [1] 289877 0
26/02/2013
Ethics approval number [1] 289877 0
12/13

Summary
Brief summary
The study aims to investigate the effects of short term supplementation with either palm-tocotrienol or palm-carotene on blood vessel function and cardiovascular disease risk in participants at risk of impaired vascular function.

We hypothesise that supplementation with both palm-tocotrienol and palm-carotene will improve blood vessel function and cardiovascular disease risk factors compared to a control supplement.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 42902 0
Dr Mahinda Abeywardena
Address 42902 0
CSIRO Animal, Food and Health Sciences
PO Box 10041
Adelaide
South Australia
5000
Country 42902 0
Australia
Phone 42902 0
+61 8 8303 8889
Fax 42902 0
Email 42902 0
mahinda.abeywardena@csiro.au
Contact person for public queries
Name 42903 0
Dr Welma Stonehouse
Address 42903 0
CSIRO Animal, Food and Health Sciences
PO Box 10041
Adelaide
South Australia
5000
Country 42903 0
Australia
Phone 42903 0
+61 8 8303 8919
Fax 42903 0
Email 42903 0
welma.stonehouse@csiro.au
Contact person for scientific queries
Name 42904 0
Dr Welma Stonehouse
Address 42904 0
CSIRO Animal, Food and Health Sciences
PO Box 10041
Adelaide
South Australia
5000
Country 42904 0
Australia
Phone 42904 0
+61 8 8303 8919
Fax 42904 0
Email 42904 0
welma.stonehouse@csiro.au

No data has been provided for results reporting
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary